Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Highlights

02-12		FA
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE
02-12	European Commission Approves Amgen's UPLIZNA for Generalized Myasthenia Gravis	CI
02-04	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
02-04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
02-03	Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln	RE
02-03	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026	CI
02-03	Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost	DJ
02-03	Amgen Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance	MT
02-03	Amd reports fourth quarter and full year 2025 financial results	RE
02-03	(AMGN) Amgen Expects 2026 Adjusted EPS Range $21.60-$23.00, vs. FactSet Est of $20.63	MT
02-03	Earnings Flash (AMGN) Amgen Inc. Reports Q4 Revenue $9.87B, vs. FactSet Est of $9.47B	MT
02-03	Earnings Flash (AMGN) Amgen Inc. Posts Q4 Adjusted EPS $5.29 per Share, vs. FactSet Est of $4.73	MT
02-03	Amgen Inc. Provides Earnings Guidance for the Fiscal Year 2026	CI
02-03	Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011.	CI
02-03	(AMGN) Amgen Expects 2026 Revenue Range $37B-$38.4B, vs. FactSet Est of $37.19B	MT
02-03	Amgen Q4 results beat Street estimates, company says patients need weight-loss options	RE
02-03	Amgen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-03	Obesity stocks slump on Novo's underwhelming 2026 sales forecast	RE
02-03	Brace for the Earnings Flood
02-03	Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings	MT
02-03	Deals and delays	RE
02-03	A swift purge, and straight back on track?
01-30	Diary - U.S. earnings week ahead	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Highlights

Filters